Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?
Introduction: Rituximab (RTX), initially approved for various blood cancers, is additionally used for the management of primary central nervous system (CNS) demyelinating disorders. This study aimed to quantify the % of B cells following RTX therapy in patients with primary CNS demyelinating disorde...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Series: | Annals of Medical Science and Research |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/amsr.amsr_36_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|